Exploring the therapeutic potential of xanthine oxidase inhibitor allopurinol in angina

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN15253766

Enrollment

Registered

2006-03-29

Start date

2006-01-05

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic stable angina Circulatory System Chronic stable angina

Interventions

Allopurinol versus placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Documented coronary artery disease 2. Chronic stable angina

Exclusion criteria

Exclusion criteria: 1. Left ventricular systolic dysfunction 2. Renal failure 3. Concomitant warfarin therapy 4. Allergy to allopurinol

Design outcomes

Primary

Measure	Time frame
Change in endothelial function as assessed by: 1. Flow-mediated dilatation 2. Forearm venous occlusion plethysmography	—

Secondary

Measure	Time frame
Changes in brain natriuretic peptide (BNP)	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 28, 2026